Advertisement

Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant

  • Xiaorui Chen
  • Bo Li
  • Jinfei Yu
  • Yue Zhang
  • Zujian Mo
  • Tiejun Gu
  • Wei Kong
  • Yong ZhangEmail author
  • Yongge WuEmail author
Original Investigation
  • 40 Downloads

Abstract

Streptococcuspneumoniae, or pneumococcus, is a major respiratory-tract pathogen that causes high levels of mortality and morbidity in infants and elderly individuals. Despite the development of various capsular polysaccharide vaccines to prevent pneumococcal disease, it remains epidemic. Pneumococcal surface protein A (PspA) is a highly immunogenic surface protein existing in all strains of S. pneumoniae, and it can elicit immunizing protection against pneumococcal infection. In our previous studies, a fusion protein (PsaA-PspA23), consisting of PspA and pneumococcal surface antigen A (PsaA), displayed greater immunogenicity and provided better protection in mice against S. pneumoniae strains than either PsaA or PspA. In this study, the fusion protein PsaA-PspA23, together with PspA4, was formulated with four adjuvants Al(OH)3, MF59, AS03, and AS02, and subsequently subjected to dose optimization and immunological evaluation for determination of the antibody titers, bacterial burden, survival rates, and levels of cytokines in mice. All vaccines with high adjuvant doses displayed higher antigen-specific immunoglobulin G (IgG) titers. Bacterial burdens were notably decreased to different extents in the lungs and blood of mice immunized with the antigen and various adjuvants. Among these adjuvants, AS02 provided outstanding protection against challenge with pathogenic bacteria from different families and clades; it also induced high titers of IgG1 and IgG2a. Moreover, only AS02 elicited high levels of cytokines, such as TNF-α, IFN-γ, IL-2, and IL-4. These results suggest that PsaA-PspA23 and PspA4 formulated with AS02 may potentially be used as a subunit vaccine against deadly pneumococcal infection.

Keywords

Streptococcus pneumoniae Pneumonia PspA Adjuvant 

Notes

Acknowledgements

We are grateful for support from Jilin Provincial Industrial Innovation Special Project for the New Vaccine Adjuvant Innovation Technology Platform (Grant No. 2018C004).

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Ethical standards

All mouse experiments in this paper were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council).

References

  1. 1.
    Pletz MW, Maus U, Krug N, Welte T, Lode H (2008) Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 32:199–206CrossRefGoogle Scholar
  2. 2.
    Pichichero ME (2017) Pneumococcal whole-cell and protein-based vaccines: changing the paradigm. Expert Rev Vac 16:1181–1190CrossRefGoogle Scholar
  3. 3.
    Zhanel GG, James KD, Karlowsky WA (2015) Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 3170Google Scholar
  4. 4.
    Bryce J, Boschi-Pinto C, Shibuya K, Black RE (2005) WHO estimates of the causes of death in children. Lancet 365:1147–1152CrossRefGoogle Scholar
  5. 5.
    Lin H, Peng Y, Lin Z, Zhang S, Guo Y (2015) Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae. Microb Pathogen 83–84:35–40CrossRefGoogle Scholar
  6. 6.
    Shinefild RH, Steve Black M (2000) Efficacy of pneumococcal conjugate vaccines in largescale field trials. Pediatr Infect Dis J 19:394–397CrossRefGoogle Scholar
  7. 7.
    Hsu HE et al (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. The New Engl J Med 360:244–256CrossRefGoogle Scholar
  8. 8.
    Janulczyk R, Iannelli F, Sjoholm AG, Pozzi G, Bjorck L (2000) Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function. J Biol Chem 275:37257–37263CrossRefGoogle Scholar
  9. 9.
    Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS (2001) PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69:3435–3437CrossRefGoogle Scholar
  10. 10.
    McKay JT et al (2015) PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. J Immunol 194:2289–2299CrossRefGoogle Scholar
  11. 11.
    Crain MJ et al. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. 58, 3293–3299 (1990)Google Scholar
  12. 12.
    Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immunol 67:4720–4724 (1999)Google Scholar
  13. 13.
    Croney CM, Coats MT, Nahm MH, Briles DE, Crain MJ (2012) PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vac Immunol: CVI 19:891–896CrossRefGoogle Scholar
  14. 14.
    Ren B, Szalai AJ, Hollingshead SK, Briles DE (2003) Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72:114–122CrossRefGoogle Scholar
  15. 15.
    Moreno AT et al (2010) Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vac Immunol 17:439–446CrossRefGoogle Scholar
  16. 16.
    Briles DE et al (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 182:1694–1701CrossRefGoogle Scholar
  17. 17.
    Goulart C et al (2011) Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 29:1634CrossRefGoogle Scholar
  18. 18.
    Whaley MJ et al (2010) Concomitant administration of recombinant PsaA and PCV7 reduces Streptococcus pneumoniae serotype 19A colonization in a murine model. Vaccine 28:3071CrossRefGoogle Scholar
  19. 19.
    Oliveira MLS et al (2006) Induction of systemic and mucosal immune response and decrease in Streptococcus pneumoniae colonization by nasal inoculation of mice with recombinant lactic acid bacteria expressing pneumococcal surface antigen A. Microbes Infection 8:1016–1024CrossRefGoogle Scholar
  20. 20.
    Lu J et al (2015) Protective immune responses elicited by fusion protein containing PsaA and PspA fragments. Immunological investigations 44:482CrossRefGoogle Scholar
  21. 21.
    Reed SG, Orr MT, Fox CB (2013) Key roles of adjuvants in modern vaccines. Nat Med 19:1597–1608CrossRefGoogle Scholar
  22. 22.
    Shi L, Zhang YJ, Xue rui YI, Liu SR Cytotoxic T cell responses to hepatitis B virus (HBV) small surface antigen in mice. Chinese Journal of Nosoconmiology (2003)Google Scholar
  23. 23.
    Fang JH, Hora M (2000) The adjuvant MF59: a 10-year perspective gary ott. Ramachandran Radhakrishnan 42:211–228Google Scholar
  24. 24.
    Traquina P, Morandi M, Contorni M, Nest GV (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 174:1168–1175CrossRefGoogle Scholar
  25. 25.
    Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A (2008) The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 180:5402–5412CrossRefGoogle Scholar
  26. 26.
    Calabro S et al (2011) Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29:1812–1823CrossRefGoogle Scholar
  27. 27.
    Morel S et al (2011) Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29:2461–2473CrossRefGoogle Scholar
  28. 28.
    McElhaney JE et al (2013) AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13:485–496CrossRefGoogle Scholar
  29. 29.
    Yam KK et al (2016) Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice. Vaccine 34:1444–1451CrossRefGoogle Scholar
  30. 30.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P (2010) AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 51:668–677CrossRefGoogle Scholar
  31. 31.
    Moris P et al (2011) H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 31:443–454CrossRefGoogle Scholar
  32. 32.
    Rénia L et al (2009) A Randomized Trial Assessing the Safety and Immunogenicity of AS01 and AS02 Adjuvanted RTS,S Malaria Vaccine Candidates in Children in Gabon. PloS one 4:e7611CrossRefGoogle Scholar
  33. 33.
    Casimiro DR et al (2010) Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 84:2996–3003CrossRefGoogle Scholar
  34. 34.
    Beall B, Gherardi G, Facklam RR, Hollingshead SK (2000) Pneumococcal pspA sequence types of prevalent multiresistant pneumococcal strains in the United States and of internationally disseminated clones. J Clin Microbiol 38:3663–3669Google Scholar
  35. 35.
    Brandileone MC et al (2004) Typing of pneumococcal surface protein A (PspA) in Streptococcus pneumoniae isolated during epidemiological surveillance in Brazil: towards novel pneumococcal protein vaccines. Vaccine 22:3890–3896CrossRefGoogle Scholar
  36. 36.
    Hollingshead SK et al (2006) Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol 55:215–221CrossRefGoogle Scholar
  37. 37.
    Echenique J, Kadioglu A, Romao S, Andrew PW, Trombe MC (2004) Protein serine/threonine kinase StkP positively controls virulence and competence in Streptococcus pneumoniae. Infect Immun 72:2434–2437CrossRefGoogle Scholar
  38. 38.
    Miyaji EN et al (2015) Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins. Clin Vac Immunol: CVI 22:213–220CrossRefGoogle Scholar
  39. 39.
    María Claudia Vela Coral et al (2001) Pneumococcal surface protein A of invasive Streptococcus pneumoniae isolates from colombian children. Emerg Infect Dis 7:5Google Scholar
  40. 40.
    Ogunniyi AD et al (2007) Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun 75:1843–1851CrossRefGoogle Scholar
  41. 41.
    Haughney SL et al (2013) Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomaterialia 9:8262–8271CrossRefGoogle Scholar
  42. 42.
    Nabors GS et al (2000) Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743CrossRefGoogle Scholar
  43. 43.
    Oliveira MLS et al (2010) Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PloS one 5:e10863CrossRefGoogle Scholar
  44. 44.
    Leroux-Roels I et al (2015) Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine 33:577–584CrossRefGoogle Scholar
  45. 45.
    Piao Z et al (2014) Protective properties of a fusion pneumococcal surface protein A (PspA) vaccine against pneumococcal challenge by five different PspA clades in mice. Vaccine 32:5607–5613CrossRefGoogle Scholar
  46. 46.
    Gordon CL et al (2012) Comparison of immunoglobulin G subclass concentrations in severe community-acquired pneumonia and severe pandemic 2009 influenza A (H1N1) infection. Clin Vac Immunol 19:446–448CrossRefGoogle Scholar
  47. 47.
    Ekdahl K, Braconier JH, Svanborg C (1997) Immunoglobulin deficiencies and impaired immune response to polysaccharide antigens in adult patients with recurrent community-acquired pneumonia. Scand J Infect Dis 29:401–407CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Xiaorui Chen
    • 1
  • Bo Li
    • 1
  • Jinfei Yu
    • 1
  • Yue Zhang
    • 1
  • Zujian Mo
    • 1
  • Tiejun Gu
    • 1
  • Wei Kong
    • 1
  • Yong Zhang
    • 1
    Email author
  • Yongge Wu
    • 1
    Email author
  1. 1.National Engineering Laboratory for AIDS Vaccine, School of Life SciencesJilin UniversityChangchunChina

Personalised recommendations